Dawnielle Miller
Psychiatric/Mental Health · Akron, OHNPI 1730706011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 652 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 652 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$972
- plus $2K from 10 others
What the payments were for
- Food & beverage$9,47597%
- Education$2603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 89 | $1,538 |
| Alkermes, Inc. | 89 | $1,481 |
| Lundbeck LLC | 74 | $1,193 |
| Otsuka America Pharmaceutical, Inc. | 60 | $1,099 |
| AbbVie | 71 | $1,065 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 109 | $972 |
| Teva Pharmaceuticals USA, Inc. | 63 | $806 |
| Neurocrine Biosciences, Inc. | 46 | $664 |
| Indivior Inc. | 16 | $311 |
| E.r. Squibb & Sons, L.L.C. | 11 | $191 |
| Vanda Pharmaceuticals Inc. | 7 | $171 |
| Sunovion Pharmaceuticals Inc. | 6 | $60 |
| Braeburn Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Noven Therapeutics, LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
How this compares
$9,735 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 132 | $315,146 |
| Invega TrinzaPaliperidone Palmitate | 34 | $259,514 |
| Abilify MaintenaAripiprazole | 88 | $241,171 |
| RexultiBrexpiprazole | 52 | $88,996 |
| Abilify AsimtufiiAripiprazole | 16 | $80,812 |
| AristadaAripiprazole Lauroxil | 21 | $64,586 |
| VraylarCariprazine Hcl | 17 | $22,302 |
| TrintellixVortioxetine Hydrobromide | 35 | $16,192 |
| Aripiprazole | 232 | $9,772 |
| Lurasidone Hcl | 86 | $7,047 |
| CelexaCitalopram Hydrobromide | 11 | $4,891 |
| Clozapine | 71 | $4,789 |
| Fluoxetine Hcl | 126 | $3,826 |
| Varenicline Tartrate | 14 | $3,595 |
| Trazodone Hcl | 386 | $3,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,538 | $574,660166 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti, Abilify Asimtufii | $1,099 | $410,979156 claims |
| Alkermes, Inc.Aristada | $1,481 | $64,58621 claims |
| AbbVieVraylar | $1,065 | $22,30217 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $16,19235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Akron
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.